About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Miami | 11,431 Studies Near You | Clareo Health

Clinical Trials LocationsMiami

Clinical Trials in Miami

Discover 11,431 clinical trials near Miami, Florida. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 8241-8260 of 11,431 trials

COMPLETEDPhase 1< 1 mile

AG200-15 Transdermal Contraceptive Delivery System (TCDS) of Levonorgestrel and Ethinyl Estradiol

NCT01243580

Pharmacokinetics and safety of AG200-15 over two consecutive cycles of therapy will be evaluated.

Agile Therapeutics36 participantsStarted Aug 2009

Miami, Florida, United States

COMPLETEDPhase 2< 1 mile

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.

NCT00398645

This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.

GlaxoSmithKline648 participantsStarted Nov 2006

Fullerton, California, United States • Huntington Beach, California, United States • Orange, California, United States +79 more locations

Find Trials by Condition in Miami

Breast Cancerin Miami Lung Cancerin Miami Prostate Cancerin Miami Colorectal Cancerin Miami Melanomain Miami Leukemiain Miami Lymphomain Miami Pancreatic Cancerin Miami Ovarian Cancerin Miami Brain Cancerin Miami Diabetesin Miami

Data from ClinicalTrials.govTerms

COMPLETEDNA< 1 mile

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

NCT02649478

A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared with Advair Diskus® 100/50 in Subjects with Asthma

Roxane Laboratories1,430 participantsStarted Aug 2014

Glendale, Arizona, United States • Phoenix, Arizona, United States • Surprise, Arizona, United States +97 more locations

COMPLETEDPhase 1< 1 mile

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)

NCT03407105

The purpose of this study is to assess the safety and tolerability of 2 or 4 doses of MDX-010 in HIV-infected subjects

Human Immunodeficiency Virus (HIV)

Bristol-Myers Squibb24 participantsStarted Apr 2003

Los Angeles, California, United States • San Francisco, California, United States • Miami, Florida, United States +2 more locations

COMPLETEDPhase 3< 1 mile

BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

NCT02137226

Primary Objective: The primary objective of this trial is to establish an equivalence in efficacy between BI 695501 and US-licensed Humira® in patients with active Rheumatoid arthritis based on a statistical comparison of the proportion of patients meeting American College of Rheumatology 20% (ACR20) response rate at Week 12 and ACR20 response rate at Week 24 between BI 695501 and US-licensed Humira®. Secondary Objectives: The secondary objectives of this trial are to compare the efficacy, safety and immunogenicity of BI 695501 and US-licensed Humira® in patients with active RA including those undergoing the transition from US-licensed Humira® to BI 695501 after 24 weeks.

Arthritis, Rheumatoid

Boehringer Ingelheim645 participantsStarted Jan 2015

Anniston, Alabama, United States • Birmingham, Alabama, United States • Birmingham, Alabama, United States +135 more locations

TERMINATEDPhase 2/3< 1 mile

Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)

NCT00683696

The EchoCRT trial evaluates the effects of Cardiac Resynchronization Therapy (CRT) on mortality and morbidity of subjects with heart failure due to left ventricular systolic dysfunction, already receiving optimized HF medication, with a narrow QRS width (\< 130 ms) and echocardiographic evidence of ventricular dyssynchrony.

Heart FailureVentricular Dyssynchrony

Biotronik, Inc.1,680 participantsStarted Aug 2008

Concord, California, United States • Los Angeles, California, United States • Rancho Mirage, California, United States +119 more locations

COMPLETEDPhase 2< 1 mile

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

NCT01119846

The purpose of this study is to see if GSK1292263 is safe and well-tolerated when administered to type 2 diabetics, and to get preliminary information about whether it may be effective in the treatment of type 2 diabetes.

Diabetes Mellitus, Type 2

GlaxoSmithKline100 participantsStarted Jun 2009

Phoenix, Arizona, United States • Chula Vista, California, United States • Miami, Florida, United States +4 more locations

COMPLETEDPhase 2< 1 mile

An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis

NCT01772823

Approximately 200 HIV-uninfected young men who have sex with men (YMSM) at high risk of acquiring HIV infection, ages 18-22 years, inclusive, will be recruited across all participating Adolescent Medicine Trials Units (AMTU). The behavioral intervention will be assigned at the level of the site, which include Many Men, Many Voices (3MV) and Personalized Cognitive Counseling (PCC). Subjects will first complete the behavioral intervention offered at their respective site and then be provided with open label emtricitabine (FTC)/tenofovir (TDF) (Truvada®) as PrEP. Behavioral and biomedical data will be collected at baseline and 0, 4, 8, 12, 24, 36 and 48 weeks. Any subjects who become HIV infected during the course of the study will be discontinued from the study agent and followed for an additional 24 weeks after the study visit at which HIV infection is confirmed. Those subjects who meet specific bone or renal criteria at the Week 48 visit or the 24-Week HIV Seropositive visit will be followed for an additional 48 weeks in the Extension Phase to monitor longer-term outcomes of potential concerns.

University of North Carolina, Chapel Hill200 participantsStarted Nov 2012

Los Angeles, California, United States • Aurora, Colorado, United States • Miami, Florida, United States +9 more locations

COMPLETEDNA< 1 mile

Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft

NCT00435942

The purpose of this study is to evaluate the safety and efficacy of the Relay thoracic stent-graft system to treat thoracic aortic aneurysms. Efficacy will be evaluated by the device-related adverse event rate of endovascular repair (via Relay Thoracic Stent-Graft) through 1-year. Safety will be evaluated by comparing major adverse events through 1-year in subjects treated with the Relay Thoracic Stent-Graft to those who underwent surgical repair. Long term follow-up is conducted through 5 years.

Thoracic Aortic Aneurysmsand Penetrating Atherosclerotic Ulcers

Bolton Medical180 participantsStarted Jan 2007

Phoenix, Arizona, United States • Tucson, Arizona, United States • San Francisco, California, United States +24 more locations

COMPLETEDPhase 3< 1 mile

A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma

NCT00323284

The purpose of this study is to evaluate the safety and efficacy of the iStent trabecular micro-bypass stent in reducing intraocular pressure (IOP) in subjects with open-angle glaucoma or ocular hypertension and co-existing cataract.

Open-Angle Glaucoma

Glaukos Corporation240 participantsStarted Jun 2005

Beverly Hills, California, United States • Petaluma, California, United States • Sacramento, California, United States +28 more locations

COMPLETEDPhase 34.3 miles

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

NCT01480479

This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express the EGFRvIII protein) to the current standard of care (temozolomide) in patients with recently diagnosed glioblastoma, a type of brain cancer. All patients will be administered temozolomide, the standard treatment for glioblastoma. Half the patients will be randomly assigned to receive rindopepimut and half the patients will be randomly assigned to receive a control called keyhole limpet hemocyanin. Patients will be treated in a blinded fashion (neither the patient or the doctor will know which arm of the study the patient is on). Patients will be treated until disease progression or intolerance to therapy and all patients will be followed for survival.

GlioblastomaSmall Cell GlioblastomaGiant Cell Glioblastoma+2 more

Celldex Therapeutics745 participantsStarted Nov 2011

Birmingham, Alabama, United States • Mobile, Alabama, United States • Phoenix, Arizona, United States +220 more locations

COMPLETEDPhase 27.3 miles

Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

NCT02498652

This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects of RDEA3170 administered in combination with allopurinol compared with allopurinol administered alone in adult subjects with gout.

Ardea Biosciences, Inc.41 participantsStarted Jul 2015

Anaheim, California, United States • DeLand, Florida, United States • South Miami, Florida, United States +1 more locations

COMPLETEDPhase 37.3 miles

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

NCT01272219

This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Furthermore, the aim is to investigate the long term potential of liraglutide to delay the onset of type 2 diabetes in subjects diagnosed with pre-diabetes at baseline. Based on body mass index (BMI) and pre-diabetes status, subjects will be randomised to either 68 weeks (56 weeks of randomised treatment followed by a 12 week re-randomised treatment period) or 160 weeks of treatment (160 week treatment will only be applicable to subjects with pre-diabetes status at baseline).

Metabolism and Nutrition DisorderObesity

Novo Nordisk A/S3,731 participantsStarted Jun 2011

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Anaheim, California, United States +223 more locations

COMPLETEDPhase 28.5 miles

Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes

NCT02537470

This is a dose-ranging study to evaluate the efficacy, safety and tolerability of a range of doses of a biphasic formulation of remogliflozin etabonate compared to placebo, administered over 12 weeks in subjects with type 2 diabetes mellitus.

Type 2 Diabetes MellitusDiabetes Mellitus, Type 2

BHV Pharma191 participantsStarted Jul 2015

Tucson, Arizona, United States • Long Beach, California, United States • Long Beach, California, United States +16 more locations

COMPLETEDPhase 214 miles

A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00718718

The purpose of this study is to evaluate the effectiveness and safety of subcutaneous (under the skin) administration of anti-interleukin-6 monoclonal antibody (CNTO 136) in reducing signs and symptoms of participants with active rheumatoid arthritis (RA) with methotrexate (MTX) therapy.

Arthritis, Rheumatoid

Centocor, Inc.187 participantsStarted Aug 2008

Aventura, Florida, United States • Lexington, Kentucky, United States • Frederick, Maryland, United States +35 more locations

COMPLETEDPhase 225 miles

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

NCT00951015

This Phase IIb study in HIV-infected antiretroviral naive subjects will select an optimal once daily dose of GSK1349572 from a range of doses for future evaluation.

Infection, Human Immunodeficiency Virus

ViiV Healthcare208 participantsStarted Jul 2009

Phoenix, Arizona, United States • Bakersfield, California, United States • Long Beach, California, United States +32 more locations

COMPLETEDPhase 3130 miles

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

NCT01449929

This study will be conducted in approximately 468 HIV-1 infected antiretroviral therapy (ART)-naïve subjects. Subjects will be randomized 1:1 to receive dolutegravir (DTG) 50 mg once daily (approximately 234 subjects) or darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily (approximately 234 subjects), each in combination with fixed-dose dual nucleoside reverse transriptase inhibitor (NRTI) therapy (either abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC). Subjects will be stratified by screening HIV-1 RNA and background NRTI selection. The primary analysis will take place after the last subject completes 48 weeks on therapy; an additional analysis will be conducted after the last subject completes Week 96 on study.

Infection, Human Immunodeficiency Virus

ViiV Healthcare488 participantsStarted Oct 2011

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +63 more locations

COMPLETEDPhase 2468 miles

Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma

NCT01000506

The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma medications. The study will look at different doses of mepolizumab in comparison to a placebo.

GlaxoSmithKline621 participantsStarted Nov 2009

Long Beach, California, United States • Los Angeles, California, United States • Riverside, California, United States +91 more locations

COMPLETEDPhase 2485 miles

The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor

NCT00404768

Pre-Term Labor (prior to 37 weeks gestation) is the largest single cause of infant morbidity and mortality and is frequently associated with long-term disability. Oxytocin is a hormone produced by the body during labor. GSK221149A is an experimental drug that will be used to block the effects of oxytocin, and therefore pause or prevent contractions. In this study, patients with preterm labor will be given an intravenous infusion of GSK221149A over approximately 12 hours followed by an oral tablet in Parts A and B. In part C of this study, patients with preterm labor will be give an intravenous infusion of GSK221149A over approximately 48 hours. The use of a rescue tocolytic is allowed in the study.

Obstetric Labour, Premature

GlaxoSmithKline93 participantsStarted Oct 2007

Mobile, Alabama, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +54 more locations

TERMINATEDPhase 3967 miles

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study

NCT02465203

Follow-up for viral activity, changes in liver function and safety in patients with no SVR24 in feeder studies

Hepatitis C, Chronic

Novartis Pharmaceuticals105 participantsStarted Sep 2012

San Diego, California, United States • Ventura, California, United States • Honolulu, Hawaii, United States +37 more locations

PreviousPage 413 of 572Next

Heart Diseasein Miami